Published in Invest Radiol on June 01, 2009
Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol (2011) 1.25
Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer (2014) 1.18
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol (2013) 0.97
Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model. Int J Radiat Oncol Biol Phys (2011) 0.90
Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. Eur Radiol (2012) 0.88
Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. Int J Radiat Oncol Biol Phys (2012) 0.88
A mathematical model of tumor volume changes during radiotherapy. ScientificWorldJournal (2013) 0.86
Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study. Radiat Oncol (2015) 0.83
The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI. Transl Oncol (2013) 0.82
Dynamic Contrast-enhanced MR Imaging in Renal Cell Carcinoma: Reproducibility of Histogram Analysis on Pharmacokinetic Parameters. Sci Rep (2016) 0.79
Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma. Medicine (Baltimore) (2016) 0.78
Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy. J Cancer Sci Ther (2012) 0.78
Evaluating early response of cervical cancer under concurrent chemo-radiotherapy by intravoxel incoherent motion MR imaging. BMC Cancer (2016) 0.77
Role of 3T multiparametric-MRI with BOLD hypoxia imaging for diagnosis and post therapy response evaluation of postoperative recurrent cervical cancers. Eur J Radiol Open (2015) 0.77
Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol (2015) 0.77
Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging (2015) 0.76
Validation of optimal DCE-MRI perfusion threshold to classify at-risk tumor imaging voxels in heterogeneous cervical cancer for outcome prediction. Magn Reson Imaging (2014) 0.76
Can Dynamic Contrast-Enhanced MRI (DCE-MRI) and Diffusion-Weighted MRI (DW-MRI) Evaluate Inflammation Disease: A Preliminary Study of Crohn's Disease. Medicine (Baltimore) (2016) 0.75
Imaging across the life span: innovations in imaging and therapy for gynecologic cancer. Radiographics (2014) 0.75
The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K(trans) in cervical cancer is explained by plasma flow rather than vessel permeability. Br J Cancer (2017) 0.75
Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin. J Control Release (2017) 0.75
Hypoxia in cervical cancer: from biology to imaging. Clin Transl Imaging (2017) 0.75
A radiobiological model of radiotherapy response and its correlation with prognostic imaging variables. Phys Med Biol (2017) 0.75
The value of advanced MRI techniques in the assessment of cervical cancer: a review. Insights Imaging (2017) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol (1953) 12.04
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med (1999) 9.16
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (2001) 8.57
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol (1993) 3.63
Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol (2000) 2.07
Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging (1999) 1.81
Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol (1996) 1.63
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg (2001) 1.59
MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging (1999) 1.52
Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging (2001) 1.38
Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys (1996) 1.36
The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1994) 1.35
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2002) 1.34
Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology (1988) 1.30
Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol (2006) 1.28
Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol (1999) 1.26
Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging (2000) 1.24
Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest Suppl (1968) 1.24
Carcinoma of the cervix--anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol (1983) 1.23
High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol (2009) 1.15
Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys (2002) 1.11
MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging (1999) 1.10
Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. J Magn Reson Imaging (1997) 1.02
Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res (2000) 1.00
Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumour regression rate. Br J Radiol (1999) 0.98
Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology (2000) 0.96
Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy. Int J Cancer (2001) 0.95
Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother Oncol (1992) 0.94
Problems with the Clinical Staging of Carcinoma of the Cervix. Semin Radiat Oncol (1994) 0.92
Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol (1998) 0.91
An exciting and challenging role for the advanced contrast MR imaging. J Magn Reson Imaging (1999) 0.91
Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol (1988) 0.90
Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol (1996) 0.90
Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging (1998) 0.89
Classification of small contrast enhancing breast lesions in dynamic magnetic resonance imaging using a combination of morphological criteria and dynamic analysis based on unsupervised vector-quantization. Invest Radiol (2008) 0.87
In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol (1998) 0.87
[Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography]. Radiologe (1997) 0.84
Influence of controllable lifestyle on recent trends in specialty choice by US medical students. JAMA (2003) 14.06
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 4.95
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2006) 4.33
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res (2006) 4.26
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003. Acad Med (2005) 3.32
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2003) 2.77
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Administrative coding data, compared with CDC/NHSN criteria, are poor indicators of health care-associated infections. Am J Infect Control (2008) 2.38
Registration and machine learning-based automated segmentation of subcortical and cerebellar brain structures. Neuroimage (2007) 2.31
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood (2010) 2.07
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
White matter abnormalities in veterans with mild traumatic brain injury. Am J Psychiatry (2012) 1.83
A comparison of normalization techniques for microRNA microarray data. Stat Appl Genet Mol Biol (2008) 1.82
Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull (2010) 1.79
Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol (2009) 1.76
Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol (2010) 1.75
Amide proton transfer MR imaging of prostate cancer: a preliminary study. J Magn Reson Imaging (2011) 1.73
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol (2004) 1.63
In-hospital treatment of obstructive sleep apnea during decompensation of heart failure. Chest (2009) 1.63
Visualization of microvascularity in glioblastoma multiforme with 8-T high-spatial-resolution MR imaging. AJNR Am J Neuroradiol (2002) 1.60
Predicting outcomes in cervical cancer: a kinetic model of tumor regression during radiation therapy. Cancer Res (2010) 1.59
Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry (2010) 1.53
Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys (2002) 1.53
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell (2012) 1.52
Chance fracture of the upper thoracic spine. AJR Am J Roentgenol (2004) 1.52
Fully automated analysis using BRAINS: AutoWorkup. Neuroimage (2010) 1.52
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood (2007) 1.51
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med (2003) 1.51
Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke (2012) 1.46
Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys (2009) 1.46
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res (2006) 1.45
In vivo imaging of changes in tumor oxygenation during growth and after treatment. Magn Reson Med (2007) 1.42
FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer (2007) 1.41
Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol (2009) 1.39
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res (2007) 1.38
Transtheoretical model-chronic disease care for obesity in primary care: a randomized trial. Obes Res (2005) 1.38
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler Thromb Vasc Biol (2012) 1.33
A Review of Challenges in the Use of fMRI for Disease Classification / Characterization and A Projection Pursuit Application from Multi-site fMRI Schizophrenia Study. Brain Imaging Behav (2008) 1.33
Presentation, prognostic factors and patterns of failure in adult rhabdomyosarcoma. Sarcoma (2003) 1.32
Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry (2007) 1.32
IA-FEMesh: an open-source, interactive, multiblock approach to anatomic finite element model development. Comput Methods Programs Biomed (2009) 1.28
Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys (2002) 1.28
Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol (2006) 1.28
Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr Bull (2009) 1.25
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood (2009) 1.25
Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol (2011) 1.25
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol (2011) 1.25
Hippocampal volume and 2-year outcome in depression. Br J Psychiatry (2008) 1.24
Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int J Clin Exp Pathol (2010) 1.24
Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release (2006) 1.24
Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation (2008) 1.23
The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab (2010) 1.22
Effectiveness of a postdischarge care management model for stroke and transient ischemic attack: a randomized trial. J Stroke Cerebrovasc Dis (2007) 1.20
Evaluation of the GTRACT diffusion tensor tractography algorithm: a validation and reliability study. Neuroimage (2006) 1.20
Effectiveness of a group exercise program in a long-term care facility: a randomized pilot trial. J Am Med Dir Assoc (2003) 1.20
A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med (2010) 1.19
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res (2008) 1.19
Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med (2003) 1.18
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol (2013) 1.18
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis (2010) 1.17
Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke (2012) 1.17
The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol (2011) 1.17
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res (2008) 1.17
A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol (2009) 1.16
Application accuracy of computed tomography-based, image-guided navigation of temporal bone. Neurosurgery (2008) 1.15
Prevalence of exercise-induced bronchospasm in a cohort of varsity college athletes. Med Sci Sports Exerc (2007) 1.15
Malignant-lesion segmentation using 4D co-occurrence texture analysis applied to dynamic contrast-enhanced magnetic resonance breast image data. J Magn Reson Imaging (2007) 1.14
Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res (2010) 1.13
Time-of-flight magnetic resonance angiography at 7 Tesla. Invest Radiol (2008) 1.11